DA3 Using Community Pharmacies to Conduct Outcomes Research  by Ungar, WJ
Abstracts
DATA REGISTRIES AND DATA COLLECTION
AND USE ISSUES
DAI
USING MEDICATION HISTORY TO MEASURE
INDICATION BIAS
Leader S, Mallick R
Pracon, Reston, VA, USA
Although observational studies are a relatively inexpen-
sive and rapid alternative to randomized controlled trials,
critics argue that observational studies lack internal valid-
ity. For example, indication bias may limit the reliability
of outcomes data from observational studies on the cost
or safety of alternative pharmacotherapy. The workshop
will focus on the novel use of data on prior medications
to document the extent of confounding by indication.
Current research on use of anti-hypertensive and anti-
anginal medications in a Medicaid population will be
used to illustrate recommended methods for designing
and conducting observational studies. Topics covered
will include assessing and classifying the duration and
classes of prior medication history, sequencing of risk
factors and adjusting for severity of disease. The on-going
controversy over the safety of calcium channel blockers
will be examined in light of evidence on confounding by
indication. The presenters' own research will be used to
explore the evidentiary basis for current claims and
counter claims as well as the weakness of data on the key
intervening variable-exposure to the study drugs. The
workshop material is aimed at researchers with hands-on
experience using administrative databases as well as in-
dustry sponsors of outcome studies. The workshop ad-
dresses the themes of enhancing the usefulness of outcomes
research for providers and insurers by strengthening cur-
87
rent methods for identifying and eliminating systematic
biases.
DAt
THE ROLE OF PATIENT REGISTRIES IN DISEASE
MANAGEMENT AND OUTCOMES RESEARCH
Hartz SC, Huse DM
Medical Research Intemational, Burlington, MA, USA
There is growing enthusiasm for the use of health-care
claims databases representing thousands or even millions
of covered lives to assess the potential value of medical
interventions, including pharmaceuticals and disease
management programs. However, evaluations of the ef-
fectiveness and safety of such interventions conducted in
this manner may be confounded by clinical or patient dif-
ferences between treatment groups that are not captured
in readily-available databases. Patient registries designed
to meet specific research objectives can provide a more
robust source of data for outcomes research and disease
management by linking administrative databases, medical
records, patient questionnaires, death certificates, etc.
The result is comprehensive longitudinal information on
diagnosis, treatment, course of illness, outcomes, quality
of life, and costs of the diseases of interest. By seeking the
informed consent of participants the registry can also ob-
viate growing public concerns about the research use of
confidential health-care data. Workshop participants will
receive a detailed overview of the registry concept and
implementation, emphasizing its research value as well as
its potential role in support of new product development
and marketing and in the development and testing of dis-
ease management programs. Case studies of successful
registries in the fields of reproductive health, cardiovascu-
lar disease, and asthma will be used to illustrate general
principles and methods. Persons who have responsibility
for planning or conducting outcomes research or disease
management programs in the pharmaceutical industry,
hospitals, or managed care will benefit from attending
this workshop.
DAII
USING COMMUNITY PHARMACIES TO
CONDUCT OUTCOMES RESEARCH
Ungar WJ
Innovus Research Inc., Burlington, Ontario, Canada
Studies of effectiveness require that health outcomes be
measured in heterogeneous samples of patients. The
Pharmacy Medication Monitoring Program (PMMP) is
an outcomes research program which uses community
pharmacies to recruit study subjects, resulting in a broad
sample of patients treated by physicians with diverse
practice patterns. Patients are followed prospectively and
undergo repeat telephone interviews at specified inter-
vals. The purpose of this workshop is to demonstrate
how community pharmacies can be used to perform high
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quality, prospective outcomes research. The methods for
establishing a network of pharmacies, recruiting patients,
and obtaining patient informed consent will be described.
The procedures for developing telephone questionnaires
and for collecting data on a broad range of topics, such as
patient demographics, drug utilization and compliance,
prescribing patterns, health services utilization, adverse
events, quality of life, out-of-pocket expenditures and
productivity losses will be discussed. Finally, the applica-
tions of community pharmacy-based outcomes research
studies will be presented. These include pharmacoeco-
nomic evaluations for formulary registration, drug utili-
zation review for improving therapeutic regimens, devel-
oping disease management strategies for optimizing care,
patient profiling for investigating utilization and compli-
ance patterns and measuring health outcomes to assess
the impact of health policy decisions. This workshop will
benefit industrial and academic researchers engaged in
prospective pharmacoeconomic assessments, health ser-
vices evaluations and outcomes research. Individuals in-
terested in outcomes research methodology and the rela-
tionship between outcomes research and health policy
decision-making may also benefit from attending.
DA4
CONSTRUCTION OF A VALIDATED,
NORMALIZED, GRANULAR ADMINISTRATIVE
DATABASE AND ITS USE IN CLINICAL
OUTCOMES IMPROVEMENT, CLINICAL
RESEARCH, AND PHARMACOECONOMIC
RESEARCH
Morris 51. Seltzer f. Bryant D'
IPremier, Inc., Charlotte, NC, USA; -Premier Research
Worldwide, Philadelphia, PA; USA
The growth in the number of studies analyzing healthcare
costs has been exponential. However, recently published
data cast doubt about their applicability. We hypothesize
that this situation may be, in part, due to the lack of
timely, validated, standardized databases. Additionally,
many of the rigorous procedures developed to assure ve-
racity of clinical research data have not been consistently
applied to the conduct of outcomes research. Similarly,
doubts about the accuracy and timeliness of administra-
tive information may hinder its application to the pro-
cesses of clinical research. We suggest that through care-
ful construction of a clinical financial database and
judicious application of clinical research tools and prac-
tices, some of these barriers may be overcome.
This workshop aims to:
1) Describe the Perspective Comparative Database
(PCD), Premier, Inc.'s standardized nationwide
ISO-center clinical financial dataset through:
• review of the methodology by which standard
data elements are defined, normalized, mapped
and validated;
• review of the methodology by which stan-
dardized costs are validated.
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2) Describe PCD's efficacy in the research arena:
• provide examples of clinical outcomes im-
provement;
• provide examples of application to clinical re-
search in the arena of patient identification and
protocol development;
• provide examples of combination with clini-
cal research tools in performance of pharmaco-
economic studies.
3) Suggest methods by which a combined PCD/clini-
cal information database might allow for rapid ac-
quisition and analysis of pharmacoeconomic data.
This workshop is intended for industry professionals
and non-industry researchers involved in applied phar-
macoeconomics, decision support systems, and clinical
research.
DAS
DISEASE STATE MANAGEMENT TRACKER:
IMPLEMENTING, TRACKING, AND EVALUATING
CLINICAL PATHWAYS AND OUTCOMES
Ambegaonkar AJ, Day D. MainJ. Lubowski T. Yamaga C.
Van VleetJ
Clinical Pharmacy Outcomes Research, Pfizer Inc., New York,
NY, USA
Although clinical guidelines have been gaming wide-
spread acceptance as a management tool, practical diffi-
culties in implementation and measurement of outcomes
have been obstacles in their widespread use. Their com-
plexity may discourage consistent use in everyday prac-
tice, while the lack of data tracking their implementation
has limited the assessment of outcomes. Disease State
Management Tracker (DSMT) addresses these concerns
with a system that makes it easy for the practitioner to
enter patient assessments and track services received, as
well as monitor patient progress and outcomes. DSMT is
based on the components of disease state management,
namely: treatment algorithms, clinical decision making,
and outcomes reporting.
Complex treatment algorithms are easily stored and
analyzed using either retrospective or prospective data.
The DSMT software was developed as an application for
the Windows 9S/NT environment. The workshop will be
presented in the form of an overview of the DSMT and its
functionalities while using community acquired pneumo-
nia as an example disease state. The attendee will be able
to convert locally or nationally developed clinical path-
ways and enter them into the DSMT. Next, patient as-
sessment, assignment into management cells for provision
of services, and determination of patient outcomes in the
DSMT will be reviewed. Finally the capability of DSMT
to generate extensive reports will be demonstrated. Some
standard reports include determination of cost of treat-
ment via the clinical pathway as well as cost of deviations
from the pathway. DSMT is being used for various dis-
ease states including community acquired pneumonia,
asthma, osteo-arthritis, osteoporosis as well as in several
